Role Of The Multi-Gene Panel Testing For Detection Of Pathogenic Variants In Patients With Hereditary Bilateral Breast Cancer

Bilateral breast cancer (BBC) is generally uncommon (1-2.6% of all patients with breast cancer), but its incidence increases particularly by up to 3% in BRCA1 or BRCA2 pathogenic variant (PV) carriers. The aim of our study was to evaluate whether all BBC patients should be offered multi-gene panel testing, regardless the criteria concerning the age at diagnosis, and personal and family history of cancer established by the current guidelines.